Palvella reports QTORIN rapamycin improves disease severity in children in phase 3 SELVA study
PVLA•Palvella said pediatric analyses from the phase 3 SELVA study showed improved overall disease severity and lesion characteristics in children with microcystic lymphatic malformations. The company plans to present the analyses on Oct. 15, 2026; QTORIN rapamycin remains investigational.
1. Pediatric study analyses
Palvella Therapeutics will present previously reported QTORIN rapamycin trial results with new pediatric analyses at PeDRA on Oct. 15, 2026. In phase 3 SELVA, the analyses showed improved overall disease severity and lesion characteristics in children with microcystic lymphatic malformations.
2. Phase 2 findings
Pediatric analyses from the phase 2 TOIVA study showed reduced disease severity and lesion bleeding in previously treated children with cutaneous venous malformations. QTORIN rapamycin remains investigational, and neither condition has an FDA-approved therapy.
